TALIS BIOMEDICAL CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.15 USD | +1.36% |
|
-0.54% | +22.82% |
| 05-08 | Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-02 | North American Morning Briefing : Stocks Seen -2- | DJ |
Talis Biomedical Corporation is a molecular diagnostic company. The Company is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +22.82% | 16.67M | |
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- TLIS Stock
- News Talis Biomedical Corporation
- Talis Biomedical : CEO Brian Coe Steps Down; Kim Popovits to Serve as Interim CEO
